IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
Top Page
IDEAYA Biosciences
(NASDAQ:IDYA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$35.00
▲(11.50% Upside)
Action:ReiteratedDate:02/18/26
The score is driven primarily by mixed financial performance—strong balance sheet strength offset by continued losses and weak cash flow quality. Technicals are a clear headwind with bearish momentum and the stock trading below key moving averages, while corporate updates provide some support via funded clinical progress despite the GSK collaboration termination. Valuation is difficult to assess due to negative earnings and no dividend.
Positive Factors
Strong balance sheet
IDEAYA’s balance sheet shows very low leverage and substantial equity, giving durable financial flexibility to fund multi-year clinical programs without immediate reliance on dilutive capital. This reduces execution risk for registrational trials and supports strategic optionality through 2–6+ months.
Negative Factors
Persistent unprofitability
Despite recent revenue uptick, IDEAYA remains loss‑making with deep negative margins, indicating the company’s capital base is not yet producing returns. Continued operating losses may require further financing if clinical progress stalls, increasing dilution and long‑term shareholder risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
IDEAYA’s balance sheet shows very low leverage and substantial equity, giving durable financial flexibility to fund multi-year clinical programs without immediate reliance on dilutive capital. This reduces execution risk for registrational trials and supports strategic optionality through 2–6+ months.
Read all positive factors
IDEAYA Biosciences (IDYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.76B
Dividend YieldN/A
Average Volume (3M)923.75K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth5376.27%
EPS Growth20.97%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.94
Shares Outstanding87,814,026
10 Day Avg. Volume1,019,419
30 Day Avg. Volume923,746
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)2.99
Price to Sales (P/S)13.99
P/FCF Ratio-41.64
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue12.34
Enterprise Value/Gross Profit12.61
Enterprise Value/Ebitda-22.42
Forecast
1Y Price Target
$55.11Price Target Upside75.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.96
Revenue Forecast (FY)$36.33M
IDEAYA Biosciences Business Overview & Revenue Model
Company Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product...
How the Company Makes Money
null...
IDEAYA Biosciences Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
78
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 218.71M | 7.00M | 23.39M | 50.93M | 27.94M |
| Gross Profit | 214.12M | 3.17M | 19.38M | 48.83M | 26.22M |
| EBITDA | -154.72M | -270.64M | -108.95M | -56.55M | -48.04M |
| Net Income | -113.70M | -274.48M | -112.96M | -58.66M | -49.76M |
Balance Sheet | |||||
| Total Assets | 1.11B | 1.12B | 649.32M | 387.97M | 381.35M |
| Cash, Cash Equivalents and Short-Term Investments | 639.39M | 676.32M | 525.11M | 364.83M | 246.77M |
| Total Debt | 27.91M | 19.17M | 2.87M | 3.48M | 5.18M |
| Total Liabilities | 86.39M | 64.94M | 28.23M | 38.51M | 79.83M |
| Stockholders Equity | 1.02B | 1.06B | 621.09M | 349.45M | 301.51M |
Cash Flow | |||||
| Free Cash Flow | -73.47M | -251.44M | -117.59M | -90.62M | -58.42M |
| Operating Cash Flow | -71.10M | -247.58M | -115.22M | -87.17M | -55.78M |
| Investing Cash Flow | 69.98M | -502.56M | -158.46M | -33.40M | -69.67M |
| Financing Cash Flow | 29.78M | 677.55M | 362.72M | 97.17M | 145.45M |
IDEAYA Biosciences Technical Analysis
Negative
31.39
Price Trends
33.31
Negative
33.60
Negative
29.18
Positive
Market Momentum
-0.37
Positive
42.83
Neutral
25.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Negative. The current price of 31.39 is below the 20-day moving average (MA) of 33.17, below the 50-day MA of 33.31, and above the 200-day MA of 29.18, indicating a neutral trend. The MACD of -0.37 indicates Positive momentum. The RSI at 42.83 is Neutral, neither overbought nor oversold. The STOCH value of 25.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDYA.
IDEAYA Biosciences Risk Analysis
IDEAYA Biosciences disclosed 76 risk factors in its most recent earnings report. IDEAYA Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IDEAYA Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $2.82B | -228.91 | -10.26% | ― | 129.21% | 80.35% | |
56 Neutral | $5.10B | -29.60 | -179.00% | ― | ― | -40.75% | |
54 Neutral | $2.35B | -34.27 | -7.31% | ― | -84.07% | -157.71% | |
52 Neutral | $2.76B | -26.90 | -11.10% | ― | 5376.27% | 20.97% | |
52 Neutral | $1.73B | -3.82 | -31.07% | ― | 36.26% | -158.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.54B | -39.23 | -79.16% | ― | 114.22% | 77.02% |
* Healthcare Sector Average
IDYA
IDEAYA Biosciences
31.39
13.95
79.99%
AGIO
Agios Pharma
29.59
-0.81
-2.66%
TVTX
Travere Therapeutics
27.56
6.77
32.56%
CELC
Celcuity
110.22
99.78
955.75%
ARQT
Arcutis Biotherapeutics
22.74
6.27
38.07%
BEAM
Beam Therapeutics
23.12
1.21
5.52%
IDEAYA Biosciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
IDEAYA updates precision oncology strategy at JPM 2026
Positive
Jan 12, 2026
On January 12, 2026, IDEAYA Biosciences posted an updated corporate presentation for investors in connection with the JPM 2026 Annual Healthcare Conference, outlining its strategy to build a leading precision oncology franchise and detailing progr...
Business Operations and Strategy
IDEAYA sets 2026 objectives to advance registrational trials
Positive
Jan 12, 2026
On January 11, 2026, IDEAYA Biosciences outlined its 2026 corporate objectives, highlighting plans to advance four registrational trials, including darovasertib across the uveal melanoma disease continuum and IDE849 as a monotherapy in neuroendocr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.